Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia

NCT04832100 is registered in ClinicalTrials.gov with Kaohsiung Medical University Chung-Ho Memorial Hospital as lead sponsor.

NCT NCT04832100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04832100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia
Lead sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2021
Completion date
June 30, 2027
Enrollment
245 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia, primary, lipidomics, metabolomics, oxidative stress, pain, soreness, muscle